Panitumumab

Drug Profile

Panitumumab

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; E7.6.3; rHuMAb-EGFr; Vectibix

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Bladder cancer; Breast cancer; Neuroendocrine tumours
  • Phase I Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 29 Nov 2016 Updated results from the phase III ASPECCT trial in Colorectal cancer presented at the 28th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
  • 10 Oct 2016 Retrospective analyses of efficacy data from the phase III PRIME trial and phase II PEAK trial in Colorectal cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Oct 2016 Phase-II clinical trials in Breast cancer (Combination therapy) in USA (IV) (NCT02876107)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top